Clinical Trials in Immune Tolerance
The ITN accepts Concept Proposals year-round for novel clinical trials with testable hypotheses that are designed to induce immune tolerance in allergy and asthma, autoimmune disease, transplantation and type 1 diabetes. In addition, the ITN accepts proposals for the development of novel tolerance assays or mechanistic studies for the purposes of establishing new surrogate biomarkers of immune tolerance and investigating the mechanisms of clinical tolerance.
Clinical Trials of Desensitization in Solid Organ Tranplantation
Deadline: August 17, 2018
Detailed information and instructions: RFP - Clinical trials for novel therapeutic approaches to induce B cell tolerance in patients who are donor-sensitized and/or to prevent sensitization.
Proposals should be submitted to Philip Bernstein, Executive Director of Strategic Review, Planning, and Communications.
Information about the ITN’s approach to tolerance in each therapeutic area (allergy, autoimmune disease, type 1 diabetes and solid organ transplantation) can be found in ITN's Strategic Plans.
Concept Proposal guidelines and templates can be found on here.